Search PubMed⌕ Search

Biomedical subjects

C Zoja

Publications and source records attributed to C Zoja.

92 records · Page 6Linked to original sources

[The role of endothelin in the progression of the renal disease in an experimental model of chronic kidney failure].

Recent in vitro and in vivo data suggest that endothelin, a potent vasoconstrictor peptide originally isolated from cultured porcine aortic endothelial cells, may be one of the factors accounting for progressive glomerulosclerosis in experimental and human glomerulopathies. Endothelin is expressed and produced by glomerular endothelial and mesangial cells in culture, has a mitogenic effect on mesangial cells and stimulates mesangial synthesis of extracellular matrix components such as type I, III and IV collagen and laminin. In rats with renal mass ablation, a model of chronic renal disease characterized by systemic hypertension, proteinuria and progressive glomerulosclerosis, a significant increase in urinary excretion of endothelin was documented 45 days after surgery as compared with basal values. Experiments involving the infusion of labeled endothelin into renal arteries of rats with renal mass ablation have suggested that the enhanced urinary excretion rate of endothelin could reflect an increased renal production of the peptide. Recent experiments done with Northern blot analysis have evidenced a 2.5 fold increase in pre-proendothelin transcript in kidney homogenates from rats with remnant kidney at 30 days after surgery. The increase averaged 4-5 fold at 60 and 120 days. In the same animals a significant correlation was found between urinary endothelin excretion and the percent of glomeruli affected by glomerulosclerosis. We conclude that the progression of renal disease after surgical ablation of renal mass is associated with an increased renal endothelin gene expression together with excessive urinary excretion of the corresponding protein. It is speculated that endothelin may mediate glomerular structural abnormalities associated with the progression of renal disease.

Animals↗

Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.

In nonimmunological models of renal damage, abnormal traffic of proteins through the glomerular capillary is one of the possible causes of renal disease progression. Here we investigated whether in a model of immune-mediated glomerulonephritis long-lasting proteinuria resulted in renal structural damage and whether chronic treatment with perindopril, an angiotensin-converting enzyme (ACE) inhibitor, lowered proteinuria and retarded disease progression. Passive Heymann nephritis (PHN), a model of human membranous nephropathy, was induced with 0.5 ml/100 g of rabbit anti-Fx1 A antibody in 26 male Sprague-Dawley rats. Animals were then divided into two groups of 13 rats each, given daily vehicle or perindopril (1 mg/kg p.o). Treatment started at day 7 when proteinuria was already present and lasted 12 months. An additional group of normal rats was used as control. Renal biopsies were taken at months 8 and 12. Untreated PHN rats showed a significant increase in systolic blood pressure starting from month 8, that was normalized by perindopril administration. Urinary protein excretion progressively increased with time in untreated PHN rats that developed focal and segmental glomerulosclerosis and tubulointerstitial damage. Perindopril significantly reduced proteinuria and limited glomerular and tubulointerstitial injury. Urinary excretion of endothelin-1 (ET-1) and transforming growth factor-beta 1 (TGF-beta 1), two major mediators of renal damage in other models of glomerulonephritis, increased with time in PHN but only the former correlated with the degree of glomerulosclerosis. The effect of perindopril on proteinuria and renal structural damage was associated with a significant reduction in urinary ET-1 but not TGF-beta 1, suggesting that ET-1 may be an important determinant of disease progression in experimental membranous nephropathy.

Angiotensin-Converting Enzyme Inhibitors↗